Editas Medicine Inc (NASDAQ:EDIT) price on Wednesday, April 30, rose 6.45% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.65.
A look at the stock’s price movement, the close in the last trading session was $1.55, moving within a range at $1.45 and $1.655. The beta value (5-Year monthly) was 2.164. Turning to its 52-week performance, $6.69 and $0.91 were the 52-week high and 52-week low respectively. Overall, EDIT moved 42.24% over the past month.
Editas Medicine Inc’s market cap currently stands at around $138.12 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-04.
Turning to the stock’s technical picture we see that short term indicators suggest on average that EDIT is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 6 recommend EDIT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
EDIT’s current price about 24.67% and 9.77% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.49, while 7-day volatility ratio is 10.03% and 11.22% in the 30-day chart. Further, Editas Medicine Inc (EDIT) has a beta value of 2.16, and an average true range (ATR) of 0.15. Analysts have given the company’s stock an average 52-week price target of $5, forecast between a low of $5 and high of $5. Looking at the price targets, the low is -203.03% off current price level while to achieve the yearly target high, price needs to move -203.03%. Nonetheless, investors will most likely welcome a -203.03% jump to $5 which is the analysts’ median price.
If we refocus on Editas Medicine Inc (NASDAQ:EDIT), historical trading data shows that trading volumes averaged 1.62 over the past 10 days and 3.67 million over the past 3 months. The company’s latest data on shares outstanding shows there are 83.71 million shares.
The 0.93% of Editas Medicine Inc’s shares are in the hands of company insiders while institutional holders own 62.07% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 12.67 million on 2025-04-15, giving us a short ratio of 5.89. The data shows that as of 2025-04-15 short interest in Editas Medicine Inc (EDIT) stood at 1517.0 of shares outstanding, with shares short falling to 13.15 million registered in 2025-03-14. Current price change has pushed the stock 29.92% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the EDIT stock continues to rise going into the next quarter.
